MOLOGEN Forschungs-, Entwicklungs-und Vertriebs GmbH – Trademark Portfolio
Entity Type: 03
MOLOGEN Forschungs-, Entwicklungs-und Vertriebs GmbH holds 2 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 42 (Computer & Scientific) — 2 filings in this category. The portfolio also extends into Class 5 (Pharmaceuticals) across 4 Nice Classification classes. The owner is based in D-20354 Hamburg.
Warburgstrasse 50
D-20354 Hamburg , DE
Showing of trademarks Trademarks
Trademark Classifications
MOLOGEN Forschungs-, Entwicklungs-und Vertriebs GmbH's trademark portfolio spans 4 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Scientific and technological services; industrial analysis and research services
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Chemical products for industry, science, photography, agriculture, horticulture and forestry
Scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments
Frequently Asked Questions
How many trademarks does MOLOGEN Forschungs-, Entwicklungs-und Vertriebs GmbH have?
MOLOGEN Forschungs-, Entwicklungs-und Vertriebs GmbH has 2 U.S. trademarks filed with the USPTO.
What trademark classes does MOLOGEN Forschungs-, Entwicklungs-und Vertriebs GmbH file in?
MOLOGEN Forschungs-, Entwicklungs-und Vertriebs GmbH files trademarks across 4 Nice Classification classes. The most active classes are Class 42 (Computer & Scientific), Class 5 (Pharmaceuticals), Class 1 (Chemicals), Class 9 (Computers & Electronics). Class 42 covers scientific and technological services; industrial analysis and research services.
What is MOLOGEN Forschungs-, Entwicklungs-und Vertriebs GmbH's trademark registration success rate?
MOLOGEN Forschungs-, Entwicklungs-und Vertriebs GmbH has a 0% trademark registration rate, with 0 out of 2 resolved applications resulting in successful registration. Currently, 0 applications are pending review.